76 results match your criteria ivt anti-vegf


Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes.

Eye (Lond) 2021 Jul 9. Epub 2021 Jul 9.

Bayer Plc, Reading, UK.

Objectives: DRAKO (NCT02850263) is a 24-month, prospective, non-interventional, multi-centre cohort study which enroled patients diagnosed with centre-involving diabetic macular oedema (DMO). The study aims to evaluate standard of care with intravitreal aflibercept (IVT-AFL) treatment in the UK. This analysis describes the anti-vascular endothelial growth factor (anti-VEGF) treatment-naive patient cohort after 12-month follow-up. Read More

View Article and Full-Text PDF

Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study.

Acta Ophthalmol 2021 Jun 14. Epub 2021 Jun 14.

EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), Saint-Denis, France.

Purpose: To describe the sociodemographic, medical and management characteristics of patients using intravitreal (IVT) anti-vascular endothelial growth factors (VEGF) in France.

Methods: An observational study was conducted in patients treated with IVT ranibizumab or aflibercept, aged 18 years or older using the French National Health Insurance Databases covering 99% of the French population. Patients currently treated in 2018 were included in a cross-sectional approach to describe treatment history over the previous 6 years. Read More

View Article and Full-Text PDF

Results of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Inflammatory Choroidal Neovascularization.

J Curr Ophthalmol 2021 Jan-Mar;33(1):68-74. Epub 2021 Mar 26.

Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia.

Purpose: To report the visual outcomes of intravitreal (IVT) anti-vascular endothelial growth factor (anti-VEGF) in inflammatory choroidal neovascularization (iCNV).

Methods: A retrospective study of 43 eyes of 38 patients with active choroidal neovascularization (CNV) related to ocular inflammatory disease, treated with IVT injections of anti-VEGF (bevacizumab, ranibizumab, or aflibercept), with or without associated systemic anti-inflammatory therapy, at Fattouma Bourguiba University Hospital, Monastir, Tunisia (24 eyes of 23 patients) and at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy (19 eyes of 15 patients) from January 1, 2013, to December 31, 2018.

Results: The mean age was 35. Read More

View Article and Full-Text PDF

Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT.

Int J Retina Vitreous 2021 Jun 2;7(1):43. Epub 2021 Jun 2.

Universitäts-Augenklinik Tübingen, Elfriede-Aulhorn-Straße 7, 72076, Tübingen, Germany.

Objective: To develop and validate a questionnaire for the investigation of non-adherence (NA) barriers in patients receiving intravitreal injection (IVT).

Design: Questionnaire development and cross-sectional patient survey combined with a retrospective medical chart review.

Participants: German patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) receiving anti-vascular endothelial growth factor (anti-VEGF) treatment via IVT. Read More

View Article and Full-Text PDF

Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats.

Mol Pharm 2021 06 20;18(6):2208-2217. Epub 2021 May 20.

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.

The current standard of care for antivascular endothelial growth factor (VEGF) treatment requires frequent intravitreal (IVT) injections of protein therapeutics, as a result of limited retention within the eye. A thorough understanding of the determinants of ocular pharmacokinetics (PK) and its translation across species is an essential prerequisite for developing more durable treatments. In this work, we studied the ocular PK in macaques of the protein formats that comprise today's anti-VEGF standard of care. Read More

View Article and Full-Text PDF

Iatrogenic Retinal Penetration from Intravitreal Injections.

Case Rep Ophthalmol 2021 Jan-Apr;12(1):248-253. Epub 2021 Apr 12.

Department of Surgery, University of Illinois College of Medicine, Peoria, Illinois, USA.

We present 2 cases of iatrogenic retinal penetration from intravitreal (IVT) injections in a retrospective noncomparative case series of 2 patients. The first patient, an 81-year-old Caucasian male, developed dense vitreous hemorrhage soon after receiving an IVT bevacizumab injection for macular edema from central retinal vein occlusion. A 25-g vitrectomy 1 week later showed a retinal hole surrounded by fresh hemorrhages in the same quadrant as the IVT injection. Read More

View Article and Full-Text PDF

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland.

Graefes Arch Clin Exp Ophthalmol 2021 May 4. Epub 2021 May 4.

Berner Augenklinik Am Lindenhofspital, Bremgartenstrasse 119, CH - 3012, Bern, Switzerland.

Objective: To assess the long-term visual outcomes in eyes with symptomatic diabetic macular oedema (DME) under intravitreal treatment (IVT) in a clinical routine setting.

Methods: Patients with newly diagnosed DME were included in this retrospective study if they had received at least three IVTs and a follow-up period ≥ 2 years. Due to altered treatment patterns since the approval of ranibizumab for DME in 2012, patients were subdivided according to their first IVT before 2013 (group 1) or thereafter (group 2). Read More

View Article and Full-Text PDF

[Contribution of respiratory relaxation techniques during intravitreal injections: A pilot study].

J Fr Ophtalmol 2021 Jun 8;44(6):842-848. Epub 2021 Apr 8.

Service de chirurgie ambulatoire, centre hospitalier d'Avranches-Granville, Granville, France. Electronic address:

Purpose: To study the effects of breathing techniques for anxiety, perceived pain, and patient satisfaction while receiving intravitreal injections.

Method: This prospective, randomized clinical study included patients admitted for intravitreal anti-VEGF injections. They were randomized into two groups: a relaxation group who listened to a prerecorded relaxation breathing session before and during the injection, and a control group who received the injection without a relaxation session. Read More

View Article and Full-Text PDF

[Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].

J Fr Ophtalmol 2021 May 8;44(5):626-631. Epub 2021 Apr 8.

Clinique ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France.

Introduction: The objective of this study was to analyze the reproducibility or variability of the time period to exudative recurrences in patients who were treated with intravitreal injections (IVT) of anti-VEGF (ranibizumab, aflibercept) for exudative age-related macular degeneration (AMD). The data studied included the number of recurrences per year, the time between the last IVT and the recurrence, fluctuation over time in the same patient, and changes in the therapeutic management of these exudative recurrences with regard to repeat induction therapy of three IVT, changes in monitoring protocols, and switches in anti-VEGF molecules.

Materials And Methods: We conducted a retrospective, single center, "real-life" study at the Nantes University Hospital, including 33 patients (42 eyes) between March 2012 and March 2017. Read More

View Article and Full-Text PDF

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.

BMC Ophthalmol 2021 Feb 17;21(1):90. Epub 2021 Feb 17.

Centre Hospitalier Intercommunal de Créteil, 40 Verdun avenue, Créteil, 94000, Paris, France.

Background: Anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in neovascular age-related macular degeneration (nAMD). Despite generally excellent response rates to anti-VEGF therapy, some patients do not respond or may respond suboptimally. In the case of refractory or rapidly recurring fluid in nAMD, clinicians may switch to another anti-VEGF agent. Read More

View Article and Full-Text PDF
February 2021

Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study.

Jpn J Ophthalmol 2021 May 20;65(3):344-353. Epub 2021 Jan 20.

Department of Ophthalmology, Kyushu University, Fukuoka, Japan.

Purpose: To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) versus IVT-AFL plus rescue photodynamic therapy (IVT-AFL + rPDT) in the subgroup of Japanese patients with polypoidal choroidal vasculopathy (PCV) enrolled in the PLANET study.

Study Design: A 96-week, double-masked, sham-controlled phase-3b/4 randomized clinical trial conducted at multiple centers from May 2014 to August 2016.

Patients And Methods: Patients with PCV (BCVA 73-24 ETDRS letters [20/40-20/320 Snellen]) received 3 initial monthly doses of IVT-AFL 2 mg. Read More

View Article and Full-Text PDF

Choriocapillary vascular density changes in choroidal neovascularization associated with choroidal nevus after anti-VEGF injections.

Eur J Ophthalmol 2020 Dec 18:1120672120982946. Epub 2020 Dec 18.

Eye Clinic, Department of Public Health, Federico II University, Naples, Campania, Italy.

Purpose: To evaluate choriocapillary vascular density changes in choroidal neovascularization (CNV) type 2 associated with choroidal nevus using optical coherence tomography angiography (OCT-A) before and after anti-VEGF treatment.

Methods: Observational case report.

Results: A 25-year-old woman, was referred to Eye Clinic and presented a decreased visual acuity in right eye. Read More

View Article and Full-Text PDF
December 2020

TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy.

Int J Mol Sci 2020 Dec 15;21(24). Epub 2020 Dec 15.

Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.

Transforming growth factor β1 (TGFβ1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGFβ1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) naïve to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) naïve to treatment and (6) PDR treated with IVT aflibercept. Read More

View Article and Full-Text PDF
December 2020

Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study.

Adv Ther 2021 02 16;38(2):1106-1115. Epub 2020 Dec 16.

Bayer Consumer Care AG, Basel, Switzerland.

Introduction: Neovascular glaucoma is characterized by neovascularization of the iris and anterior angle chamber. Intravitreal anti-vascular endothelial growth factor agents may decrease intraocular pressure (IOP) and improve neovascularization. The VENERA study assessed the efficacy and safety of intravitreal aflibercept (IVT-AFL) in patients with neovascular glaucoma. Read More

View Article and Full-Text PDF
February 2021

Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial.

Adv Ther 2021 02 16;38(2):1116-1129. Epub 2020 Dec 16.

Bayer Consumer Care AG, Basel, Switzerland.

Introduction: Neovascular glaucoma is characterized by neovascularization of the iris and the anterior angle chamber. Intravitreal anti-vascular endothelial growth factor agents may improve intraocular pressure (IOP) and neovascularization.

Methods: The VEGA trial assessed the efficacy and safety of intravitreal aflibercept (IVT-AFL) in patients with neovascular glaucoma in a 13-week, randomized, double-masked, sham-controlled, phase 3 study performed at multiple sites in Japan that enrolled patients with anterior segment neovascularization and IOP > 25 mmHg. Read More

View Article and Full-Text PDF
February 2021

Treatment Efficacy and Biocompatibility of a Biodegradable Aflibercept-Loaded Microsphere-Hydrogel Drug Delivery System.

Transl Vis Sci Technol 2020 10 13;9(11):13. Epub 2020 Oct 13.

Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA.

Purpose: To evaluate the in vivo treatment efficacy and biocompatibility of a biodegradable aflibercept-loaded microsphere-hydrogel drug delivery system (DDS) in a laser-induced choroidal neovascularization (CNV) rat model.

Methods: Two weeks after CNV induction, animals were randomly assigned into four experimental groups: (1) no treatment, (2) single intravitreal (IVT) injection of blank DDS, (3) bimonthly bolus IVT aflibercept injections, and (4) single IVT injection of aflibercept-DDS. CNV lesion sizes were monitored longitudinally using fluorescence angiography and multi-Otsu thresholding for 6 months. Read More

View Article and Full-Text PDF
October 2020

[Telemedicine monitoring for AMD patients].

J Fr Ophtalmol 2020 Aug 19. Epub 2020 Aug 19.

Service d'ophtalmologie CHU Rennes, 2, rue Henri-le-Guilloux, 35000 Rennes, France.

Introduction: AMD follow-up is a public health issue in developed countries due to aging of the population and medical demographics. Telemedicine may be a means of improving follow-up.

Purpose: To compare the agreement between telemedicine and in-person consultations in terms of indications for intravitreal injections in exudative AMD patients. Read More

View Article and Full-Text PDF

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD.

Mol Ther Methods Clin Dev 2020 Sep 12;18:345-353. Epub 2020 Jun 12.

Adverum Biotechnologies, Menlo Park, CA, USA.

Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance resulting from the need for repeated injections. Gene therapy may provide sustained levels of anti-VEGFA proteins in the retina following a single injection. Read More

View Article and Full-Text PDF
September 2020

Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Eye (Lond) 2020 06;34(Suppl 1):1-51

Ophthalmology, Royal Free London NHS Foundation Trust, London, UK.

The management of diabetic retinopathy (DR) has evolved considerably over the past decade, with the availability of new technologies (diagnostic and therapeutic). As such, the existing Royal College of Ophthalmologists DR Guidelines (2013) are outdated, and to the best of our knowledge are not under revision at present. Furthermore, there are no other UK guidelines covering all available treatments, and there seems to be significant variation around the UK in the management of diabetic macular oedema (DMO). Read More

View Article and Full-Text PDF

Efficacy and follow-up of anti-VEGF injections in diabetic macular edema in real-life practice at the Dijon university medical centre through the Save Sight Registries.

J Fr Ophtalmol 2020 Sep 27;43(7):618-625. Epub 2020 May 27.

The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

Purpose: To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections (IVT) in diabetic macular edema (DME) in real-life practice using the Save Sight Registries (SSR).

Material And Methods: We conducted an observational, single-centre, retrospective study in the department of ophthalmology of the Dijon University Hospital. We included treatment-naive patients who presented with DME between January 2016 and December 2017. Read More

View Article and Full-Text PDF
September 2020

Primate model of chronic retinal neovascularization and vascular leakage.

Exp Eye Res 2020 06 7;195:108031. Epub 2020 Apr 7.

Virscio, Inc., 4 Science Park, New Haven, CT 06511, USA.

The purpose of this study was to characterize and develop a primate model of chronic retinal neovascularization and vascular leakage that can be employed to assess efficacy of experimental therapeutics targeting retinal ischemic and neovascular diseases. African green monkeys received bilateral intravitreal (IVT) injection of DL-alpha-aminoadipic acid (DLAAA; 5 mg) following ophthalmic examination, color fundus photography, fluorescein angiography (FA) and optical coherence tomography (OCT). Imaging was repeated to evaluate progression and subsequent stabilization of retinal vascular pathology elicited by DLAAA. Read More

View Article and Full-Text PDF

Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.

Exp Eye Res 2020 06 6;195:108030. Epub 2020 Apr 6.

Center for Developmental Therapeutics, Northwestern University, Evanston, IL, USA. Electronic address:

Retinopathy of prematurity (ROP) is a growing cause of lifelong blindness and visual defects as improved neonatal care worldwide increases survival in very-low-birthweight preterm newborns. Advancing ROP is managed by laser surgery or a single intravitreal injection of anti-VEGF, typically at 33-36 weeks gestational age. While newer methods of scanning and telemedicine improve monitoring ROP, the above interventions are more difficult to deliver in developing countries. Read More

View Article and Full-Text PDF

Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.

Ophthalmology 2020 07 17;127(7):963-976. Epub 2020 Jan 17.

Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland.

Improving or maintaining visual acuity is the main goal for the treatment of neovascular age-related macular degeneration (nAMD). Current nAMD standard of care dictates frequent intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections, which places a substantial burden on patients, caregivers, and physicians. Brolucizumab, a newly developed anti-VEGF molecule for nAMD treatment, has demonstrated longer durability and improvement in visual and anatomic outcomes in clinical studies in a q12-week regimen, indicating its potential to reduce treatment burden as an important therapeutic tool in nAMD management. Read More

View Article and Full-Text PDF

A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition.

J Pharmacol Exp Ther 2020 05 25;373(2):184-192. Epub 2020 Feb 25.

Allergan plc, Irvine, California.

Abicipar pegol (abicipar) is a novel DARPin therapeutic and highly potent vascular endothelial growth factor (VEGF) inhibitor intended for the treatment of neovascular age-related macular degeneration (nAMD). Here we develop a translational pharmacokinetic/pharmacodynamic (PK/PD) model for abicipar to guide dosing regimens in the clinic. The model incorporated abicipar-VEGF binding kinetics, VEGF expression levels, and VEGF turnover rates to describe the ocular and systemic PK data collected from the vitreous, aqueous humor (AH), choroid, retina, and serum of rabbits after a 1-mg abicipar intravitreal (IVT) dose. Read More

View Article and Full-Text PDF

Non-invasive molecular tracking method that measures ocular drug distribution in non-human primates.

Commun Biol 2020 01 8;3(1):16. Epub 2020 Jan 8.

Department of Translational Medicine, Novartis Institutes for BioMedical Research, East Hanover, NJ, 07936, USA.

Intravitreal (IVT) injection has become the standard route for drug administration in retinal diseases. However, the ability to measure biodistribution of ocular therapeutics in large species remains limited, due to the invasive nature of some techniques or their lack of spatial information. The aim of this study was to develop in cynomolgus monkeys a non-invasive fluorescence imaging technology that enables tracking of IVT-dosed drugs and could be easily translated into humans. Read More

View Article and Full-Text PDF
January 2020

Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study.

Graefes Arch Clin Exp Ophthalmol 2020 Mar 2;258(3):521-528. Epub 2020 Jan 2.

CUDC, Hôpital Lariboisière, Paris, France.

Purpose: To report the effectiveness of intravitreal aflibercept (IVT-AFL) treatment for diabetic macular edema (DME) in French clinical practice.

Methods: APOLLON (NCT02924311) was a prospective, observational cohort study of patients with DME. Effectiveness was evaluated by change from baseline in best-corrected visual acuity (BCVA) at 12 months in treatment-naïve patients (i. Read More

View Article and Full-Text PDF

An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study.

Acta Ophthalmol 2019 Dec 6. Epub 2019 Dec 6.

Department of Ophthalmology & Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA.

Purpose: To study and compare the efficacy of different therapeutic options for the treatment of central serous chorioretinopathy (CSCR).

Methods: This is a nonrandomized, international multicentre study on 1719 patients (1861 eyes) diagnosed with CSCR, from 63 centres (24 countries). Reported data included different methods of treatment and both results of diagnostic examinations [fluorescein angiography and/or optical coherent tomography (OCT)] and best-corrected visual acuity (BCVA) before and after therapy. Read More

View Article and Full-Text PDF
December 2019

[ANDROMEDA-an investigation of factors influencing the adherence of patients with neovascular age-related macular degeneration using the newly developed patient questionnaire LAF-IVT].

Ophthalmologe 2020 Aug;117(8):765-774

Dep. of Ophthalmology, Universitäts-Augenklinik Bonn, University of Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland.

Background: Lack of adherence to treatment is a widespread problem in the anti-VEGF (Vascular Endothelial Growth Factor) treatment of patients with neovascular age-related macular degeneration (nAMD). In contrast to the extent of the lack of treatment adherence, there is so far insufficient evidence for elucidating the causes of nonadherence. The ANDROMEDA study was initiated to investigate the influencing factors on the adherence of nAMD patients to treatment. Read More

View Article and Full-Text PDF

Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study.

J Clin Med 2019 Nov 2;8(11). Epub 2019 Nov 2.

Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.

The objective was to investigate the usefulness of the "liquid biopsy" of aqueous humor (AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three groups according to their anti-VEGF response: rapid responders ( = 11), slow responders ( = 11), and non-responders ( = 9). Read More

View Article and Full-Text PDF
November 2019

Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization.

Exp Eye Res 2019 11 11;188:107798. Epub 2019 Sep 11.

Center for Developmental Therapeutics, Northwestern University, Evanston, IL, USA. Electronic address:

Abnormal migration and proliferation of endothelial cells (EC) drive neovascular retinopathies. While anti-VEGF treatment slows progression, pathology is often supported by decrease in intraocular pigment epithelium-derived factor (PEDF), an endogenous inhibitor of angiogenesis. A surface helical 34-mer peptide of PEDF, comprising this activity, is efficacious in animal models of neovascular retina disease but remains impractically large for therapeutic use. Read More

View Article and Full-Text PDF
November 2019